IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19, Influenza, and RSV infections in immunocompromised patients - PubMed
4 hours ago
- #Immunocompromised
- #Respiratory Viruses
- #Vaccination Guidelines
- IDSA 2025 Guidelines focus on vaccines for COVID-19, Influenza, and RSV in immunocompromised patients.
- Target groups include adults and children with conditions like hematologic malignancy, transplants, autoimmune diseases, and severe HIV.
- Strong recommendations for timely, age-appropriate vaccines, with guidance on optimal timing relative to immunosuppressive therapy.
- Co-administration of COVID-19, RSV, and Influenza vaccines is considered appropriate.
- Research gaps include immunogenicity, durability, and effectiveness, especially for B-cell-depleting therapies and post-transplant patients.
- Priority areas: defining protection correlates, optimizing schedules, evaluating high-dose/adjuvanted vaccines, and improving real-world data.
- Emphasis on equity and access strategies to ensure uptake among vulnerable populations.